Boston Scientific's decision to stop selling coaptite boosts Axonics stock as investors see it as a move to ease ...

The new center will offer community clinic services as well as dedicated research and teaching spaces for students across ...

Primary prevention implantable cardioverter-defibrillators (ICDs) equipped for antitachycardia pacing (ATP) offered fewer ...

Across medtech, companies have continued to innovate through the first nine months of 2024, and that rings especially true in ...

Cook Medical’s lead management business provides a comprehensive end-to-end product portfolio of medical devices and ...

In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Boston Scientific (BSX – Research ...

Northern Illinois University is getting $40 million for health sciences education and research. The gift from James and Theo ...

For our methodology, we have ranked the best healthcare stocks to buy according to hedge funds based on their total number of ...

India Pacemaker Market is flourishing due to the rising prevalence of cardiovascular diseases, growing geriatric population, increasing life expectancy, and government’s supportive reimbursement ...

Shares of Boston Scientific Corp. BSX inched 0.10% higher to $84.00 Monday, on what proved to be an all-around positive ...

This was the stock's second consecutive day of gains.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Boston Scientific (BSX – Research Report) yesterday and set a price target of $87.00. The company’s shares closed last Friday at $83.35.